INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 Russian patent published in 2020 - IPC A61K9/72 A61K38/08 A61P11/00 A61P31/00 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to infectious and internal diseases, and aims to treat COVID-19. Hexapeptide of formula (I): H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or a pharmaceutically acceptable salt thereof is used in the treatment of a respiratory disease associated with interleukin-6, where the respiratory disease is COVID-19, by pulmonary administration to a mammal in need thereof. Also for treating respiratory disease associated with interleukin-6, where the respiratory disease is COVID-19, using an aqueous pharmaceutical composition containing said hexapeptide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant, by pulmonary administration to a mammal in need thereof. Furthermore, a method of treating respiratory disease associated with interleukin-6, where the respiratory disease is COVID-19, involves a stage of pulmonary administration of an effective amount of said hexapeptide or its pharmaceutically acceptable salt to a mammal in need thereof.

EFFECT: using the group of inventions enables providing more effective prevention, reduction or elimination of the symptoms of respiratory disease associated with IL-6, where the respiratory disease is COVID-19.

9 cl, 10 ex, 6 tbl, 4 dwg